Evotec SE announced today that the Company has entered a partnership with Charité – Universitätsmedizin Berlin (“Charité”), one of the leading and largest university hospitals in Europe, to generate a molecular patient database for ANCA-associated vasculitis (“AAV”), a collection of relatively rare autoimmune diseases of unknown cause, characterised by inflammation of blood vessels. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-partnership-with-charite-to-expand-molecular-patient-database-in-autoimmune-diseases-6354